Mode
Text Size
Log in / Sign up
Phase 2 Completed N=165 Randomized Triple-blind Treatment

Combining Varenicline and Naltrexone for Smoking Cessation

Nicotine Dependence · Alcohol Use Disorder
Source: ClinicalTrials.gov NCT02698215 ↗
Enrolled (actual)
165
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Number of Participants With Expired Carbon Monoxide Level <=5ppm — 22; 37 Participants

Summary

This study is a double-blind, randomized clinical trial using a two group medication design consisting of the combination of VAR (1 mg twice daily) + NTX (50 mg once daily) and VAR (1 mg twice daily) + PLA (matched to NTX), for smoking cessation in a sample of heavy drinking daily smokers who want to quit smoking and reduce drinking.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Expired Carbon Monoxide Level <=5ppm
22; 37
SECONDARY
Drinks Per Drinking Day
3.1242; 3.5121

Eligibility Criteria

Inclusion Criteria

  • Be treatment-seeking for smoking cessation and have a desire to reduce or quit drinking
  • Be between the ages of 21 and 65
  • Be able to provide informed consent
  • Smoke 5 or more cigarettes per day for the past year
  • Currently drink heavily according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) guidelines: for men, > 14 drinks per week or ≥ 5 drinks per occasion at least once per month over the past 12 months; for women, > 7 drinks per week or ≥ 4 drinks per occasion at least once per month over the past 12 months
  • Pass the physical exam and associated laboratory tests, as determined by study physician

Exclusion Criteria

  • Have clinically significant alcohol withdrawal, indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) and assessed at the in-person screening visits
  • Have lifetime DSM-V diagnosis of schizophrenia, bipolar disorder, a psychotic disorder, or any other psychiatric disorder as determined by the clinical interview
  • Have major depressive disorder within the past year requiring treatment as determined by the clinical interview using DSM-V criteria
  • Have a current or lifetime DSM-V diagnosis of a substance use disorder, other than for alcohol or nicotine, as determined by the clinical interview
  • Have a prior history of taking FDA approved medications (i.e. varenicline or bupropion) for smoking cessation
  • Be currently using any forms of nicotine replacement therapy (past use is acceptable)
  • Be currently using tobacco products other than cigarettes (such as e-cigarettes, cigars, or chewing tobacco)
  • Have a serious medical illness (significant cardiovascular disease; uncontrolled hypertension; hepatic or renal disease) that would contraindicate participation, as determined by the study physician
  • Be currently taking insulin or oral hypoglycemic medication
  • Be currently taking opioid pain medications or any form of opioid agonist maintenance therapy (such as methadone or buprenorphine)
  • Be currently taking any other psychoactive medications; such as anti-depressants, mood stabilizers, anti-seizure medications, sedatives-hypnotics, anxiolytics, stimulants or antipsychotics
  • Have self-reported use of cocaine, methamphetamine, heroin or other illicit drugs in the previous 60 days, verified by urine toxicology screen
  • For women, must not be pregnant (as indicated by self-report or a positive pregnancy test at any study visit), nursing, or planning to become pregnant while taking part in the study, and must agree to a reliable method of birth control
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02698215). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search